Arena Pharmaceuticals — Technical Presentation (March 2018)
23 slides from Arena Pharmaceuticals's technical presentation, Mar 19, 2018
Slide 1: Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results
March 19, 2017 Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative stage drug candidate etrasimod, including its potential to become best-in-class, profile, and phase 3 program and other deve
Slide 3: Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results
March 19, 2017 Etrasimod Phase 2 in Ulcerative Colitis OASIS Clinical Trial Results
Slide 4: Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS)
Etrasimod Phase 2 Trial in Ulcerative Colitis (OASIS) Week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study 12-Week Induction Phase Exit/Transition to Extension Study 12-Week Treatment Period 1 mg q.d. etrasimod 2 mg q.d. etrasimod P
Slide 5: Endpoints Reported Today
Endpoints Reported Today Primary Endpoint: Change in 3-component Mayo Clinic Score (score ranging from 0 to 9; stool frequency, rectal bleeding, and findings on endoscopy) at Week 12 Secondary Endpoints: Proportion of patients who achieve endoscopic improvement at Week 12 Change in 2-component Mayo
Slide 6: Statistical Analysis Plan
Statistical Analysis Plan ANCOVA* model used to estimate changes in Mayo Clinic Score Mantel-Haenszel method** used to estimate proportion difference for dichotomous parameters Missing individual Mayo Clinic subscores impacting efficacy measures were imputed using multiple imputation methodology Obs
Slide 7: Patient Disposition
Patient Disposition Placebo Etrasimod 1 mg Etrasimod 2 mg Received Study Treatment, N 54 52 50 Completed Study, n (%) 48 (88.9) 47 (90.4) 46 (92.0) Early Discontinuation, n (%) 6 (11.1) 5 (9.6) 4 (8.0)
Slide 8: Baseline Characteristics
Baseline Characteristics Placebo (N=54) Etrasimod 1 mg (N=52) Etrasimod 2 mg (N=50) Mean Age, Years 44.8 43.2 40.4 Sex, n (%) Male 32 (59.3) 30 (57.7) 27 (54.0) Female 22 (40.7) 22 (42.3) 23 (46.0) Race, n (%) White 51 (94.4) 48 (92.3) 49 (98.0) Non-White 3 (5.6) 4 (7.7) 1 (2.0) Mean Weight, kg 75.7
Slide 9: Overall Safety & Tolerability
Overall Safety & Tolerability Placebo (N=54) Etrasimod 1 mg (N=52) Etrasimod 2 mg (N=50) Number (%) of Patients with any TEAE 27 (50.0) 31 (59.6) 28 (56.0) Number (%) of Patients with TEAE Leading to Discontinuation of Study Drug 0 3 (5.8) 4 (8.0) Number (%) of Patients with Serious TEAE 6 (11.1) 3
Slide 10: Cardiac Safety Summary
Cardiac Safety Summary Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block No SAEs related to HR changes or AV block were recorded Hourly ECGs on Day 1 demonstrated no mean changes in HR ≥ 10 bpm in either etrasimod group at any tim
Slide 11: Adverse Events of Special Interest
Adverse Events of Special Interest No increases in liver function tests compared to placebo No reports of macular edema No reports of abnormal pulmonary function tests
Slide 12: Primary Endpoint: 3-Component Mayo Clinic Score
Primary Endpoint: 3-Component Mayo Clinic Score Change on 9-Point Scale Including Rectal Bleeding, Stool Frequency, Endoscopy LS=least square; Δ LS mean difference from placebo. LS mean was estimated using an ANCOVA model that includes current oral corticosteroid therapy at baseline and previous exp
Slide 13: Secondary Endpoint: Endoscopic Improvement
Secondary Endpoint: Endoscopic Improvement Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists. Δ = 4.1% (p = 0.306) Δ = 24.4% (p = 0.
Slide 14: Secondary Endpoints: 2-Component Mayo Clinic Score & Total Mayo Clinic Score
Secondary Endpoints: 2-Component Mayo Clinic Score & Total Mayo Clinic Score 2-Component Mayo Clinic Score: Change on 6-point Scale (Rectal Bleeding, Endoscopy). Total Mayo Clinic Score: Change on 12-point scale (Rectal Bleeding, Stool Frequency, Endoscopy, PGA). LS=least square; Δ LS mean differenc
Slide 15: Lymphocyte Reduction
Lymphocyte Reduction Mixed effects model with current oral corticosteroid use, previous exposure to TNFa antagonists, treatment, week and treatment-by-week interaction, as factors and baseline value as covariate. All values p < 0.001
Slide 16: Clinical Remission (3-Component)
Clinical Remission (3-Component) Proportion of Patients with Endoscopy, Rectal Bleeding and Stool Frequency Mayo Clinic Subscore of ≤ 1 point and Stool Frequency Improvement of ≥ 1 point Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use
Slide 17: Clinical Remission (Total MCS)
Clinical Remission (Total MCS) Proportion of Patients with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point MCS = Mayo Clinic Score Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TN
Slide 18: Endoscopic Improvement in UC Studies of S1P Modulators
Endoscopic Improvement in UC Studies of S1P Modulators Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Etrasimod: Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists. Ozanimod: Sandb
Slide 19: Endoscopic Improvement in UC Studies
Endoscopic Improvement in UC Studies Proportion of Patients with Mayo Clinic Subscore of 0 or 1 points Etrasimod: Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use, prior exposure to TNFα antagonists. Sources: Ozanimod: Sandborn, et al.
Slide 20: Clinical Remission (Total MCS) in UC Studies of S1P Modulators
Clinical Remission (Total MCS) in UC Studies of S1P Modulators Proportion of Patients with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Total MCS = Mayo Clinic Score Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current
Slide 21: Clinical Remission (Total Mayo Clinic Score) in UC Studies
Clinical Remission (Total Mayo Clinic Score) in UC Studies Proportion of Patients with Total Mayo Clinic Score ≤ 2 points and No Subscore > 1 point Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior
Slide 22: Etrasimod 2 mg Demonstrated Statistically Significant Improvements in Multiple Clinical Endpoints
Etrasimod 2 mg Demonstrated Statistically Significant Improvements in Multiple Clinical Endpoints MCS = Mayo Clinic Score. Placebo adjusted mean changes from baseline in endpoints. Statistical testing for each clinical endpoint utilized single sided testing, with significance set at p < 0.025. Endos
Slide 23: Etrasimod Phase 2 Results Reflect a Strong Development Program and Paves Way for Phase 3
Etrasimod Phase 2 Results Reflect a Strong Development Program and Paves Way for Phase 3 We believe etrasimod has: Best S1P receptor selectivity and pharmacodynamics in the class Phase 2 data supporting best-in-class potential Clinical utility across multiple immune and inflammatory conditions Favor
Arena Pharmaceuticals — Technical Presentation (March 2018) on 6ix